Compositions and methods for treating immune thrombocytopenia
US12202900B2 · kind B2 · utility
2Cited by
38References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 7, 2019 |
| Grant date | Jan 21, 2025 |
| Priority date | — |
| Expiry date | Apr 19, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method is disclosed for the treatment of human subjects diagnosed with immune thrombocytopenia (ITP). The method comprises administering to a human subject a human neonatal Fc receptor (hFcRn) antagonist, optionally in combination with standard-of-care ITP treatment. In certain embodiments, the hFcRn antagonist is efgartigimod (ARGX-113). Standard-of-care ITP treatment may comprise administration of corticosteroids, immunosuppressants, and/or thrombopoietin receptor (TPO-R) agonists.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.